Phosphodiesterase 10A is a member of the phosphodiesterase family whose brain expression is restricted to the striatum. Phosphodiesterase 10A regulates cyclic adenosine monophosphate and cyclic guanosine monophosphate, which mediate responses to dopamine receptor activation, and the levels of these cyclic nucleotides are decreased in experimental models of L-dopa-induced dyskinesia. The elevation of cyclic adenosine monophosphate/cyclic guanosine monophosphate levels by phosphodiesterase 10A inhibition may thus be targeted to reduce L-dopa-induced dyskinesia. Obj ecti ves: The present study was aimed at determining the potential antidyskinetic effects of phosphodiesterase 10A inhibitors in a primate model of Parkinson's disease (PD). The experiments performed in this model were also intended to provide translational data for the design of future clinical trials.
changes of striatal function, 1, 6 including morphological and synaptic plasticity changes of striatal projection neurons (SPNs) [7] [8] [9] [10] as a result of chronic DA loss and replacement therapy. Studies in experimental models of LID have provided evidence for altered responses of SPNs to dopaminergic stimulation ultimately leading to imbalance of striatal outputs and the occurrence of involuntary movements. 11, 12 Clearly, the development of effective therapeutics depends on targeting these key LID mechanisms 13, 14 with selective pharmacological strategies.
DA signaling mechanisms in SPNs are mediated by the second messengers, cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP), which are regulated by phosphodiesterases (PDEs). A member of this enzyme family that hydrolyzes both cyclic nucleotides and is expressed only in the brain 15 is phosphodiesterase 10A (PDE10A). Critically, PDE10A is mainly restricted to the striatum and localized in SPNs, [15] [16] [17] a property that confers unique selectivity to regulate signaling cascades in SPNs and manipulate the striatal outputs. PDE10A inhibitors were shown to produce behavioral effects similar to D2 antagonists by increasing the activity of SPNs expressing D2 receptors (D2Rs). [18] [19] [20] However, PDE10A inhibitors can have a distinct pharmacological profile, compared with D2 antagonists, because PDE10A is expressed in both subpopulations of SPNs expressing D1R or D2R and projecting into the direct and indirect striatal output pathways, respectively. [21] [22] [23] Therefore, PDE10A inhibitors acting on both direct and indirect SPNs may have a unique impact in the dyskinetic responses to DA replacement in PD. 12, 24 Importantly, studies in rodent models showed that cAMP and cGMP significantly decrease at the peak of LID, 25, 26 and the administration of PDE inhibitor reduces LID, 26, 27 suggesting that upregulation of cAMP/cGMP could be an effective approach to treat LID.
A new potent and selective PDE10A inhibitor, MR1916 (Mochida Pharmaceuticals Co. LTD., Gotemba, Japan), has been developed in the course of extensive chemical optimization. MR1916 has potent inhibitory activities for human, rat, and monkey PDE10A with half maximal inhibitory concentration values of less than 0.1 nM and >1,000-fold selectivity against other PDEs. Additionally, MR1916 has excellent brain penetration and is active orally (see also Supplementary Information). Here, we investigated whether MR1916 effectively reduces LID in the nonhuman primate model of advanced PD for predicting anti-LID efficacy in patients. After profiling the pharmacokinetics of MR1916 and the individual optimal and suboptimal (subcutaneous) doses of L-dopa, MR1916 effects were assessed in trials of acute and chronic L-dopa coadministration and compared with amantadine effects. The selective PDE10A inhibitor, MR1916, produced a dose-dependent reduction of LID that was maintained following chronic administration. In comparison to amantadine, MR1916 had an improved pharmacological profile for the treatment of LID in parkinsonian primates.
MATERIALS AND METHODS

Nonhuman Primate Model
Five adult monkeys (Macaca fascicularis; 3 males and 2 females, the characteristics of each animal are described in Supplementary Table 1) were used in this study following the National Institutes of Health Guide for the Care and Use of Laboratory Animals (1996). All monkeys were rendered parkinsonian by repeated systemic administration of MPTP for 6 months or longer as previously described. 28 After reaching stabilization with moderate-to-severe parkinsonism over a 2-month period, monkeys received oral L-dopa (carbidopa/levodopa [Sinemet 25/100]; Merck & Co., Inc., Whitehouse Station, NJ) as maintenance treatment. On average, after 2 months of daily L-dopa treatment, all 5 animals developed consistent and reproducible LID. Subsequently, the subcutaneous optimal and suboptimal doses of L-dopa methyl ester plus benserazide (one quarter of L-dopa dose; both from Sigma-Aldrich, St Louis, MO) were determined for each animal based on their response to repeated tests of various doses. These optimal and suboptimal doses were defined as the doses that induce a reduction of motor disability scores (MDS) between 50% and 75% (optimal dose) or <50% (suboptimal dose).
Acute MR1916 and L-dopa Coadministration
All 5 animals were used in the acute trials. In trials of acute coadministration with L-dopa, MR1916 hydrobromide (Mochida Pharmaceuticals, Gotemba, Japan) was dissolved in dimethyl sulfoxide and cremophor, and injected subcutaneously at 4 escalating doses (0.0015, 0.005, 0.015, and 0.05 mg/kg). In these trials, amantadine hydrochloride (Sigma-Aldrich) was dissolved in saline and injected subcutaneously at 2 doses (5 and 10 mg/kg). 29 In each acute trial (optimal and suboptimal L-dopa dose), a vehicle injection (MR1916 at 0 mg/kg) was included as control. On test days, MR1916 or amantadine was administered subcutaneously immediately before the L-dopa methyl ester injection at the preselected subcutaneous dose. All tests were performed in the morning, and animals were fasting overnight on days of experiments. All tests were done with a minimum of a 48-hour interval to ensure adequate washout of MR1916. Oral L-dopa maintenance treatment was withheld on test days. In all acute tests, MR1916 doses (0, 0.0015, 0.005, 0.015, and 0.05 mg/kg) or amantadine doses (5 and 10 mg/kg) were tested in random order. Each treatment was repeated 3 times, and averaged data were used as results of a given treatment ( Supplementary Fig. 1 ).
Chronic MR1916 Treatment
All 5 animals received a subcutaneous injection of MR1916 (0.015 mg/kg) in the morning together with the regular oral L-dopa dose every day for 5 weeks to determine the development of tolerance or the appearance of adverse effects with chronic treatment. The dose of MR1916 for the chronic trial was selected based on results in acute trials. Once every week during this 5-week period, MR1916 was given with the suboptimal subcutaneous dose of L-dopa methyl ester instead of the oral L-dopa dose for assessment of reliable responses to subcutaneous L-dopa and accurate testing of sustained MR1916 effects or development of tolerance. 30 Responses to the treatment combination MR1916 plus subcutaneous L-dopa methyl ester were compared across the following time points: baseline (day 0: subcutaneous L-dopa methyl ester plus MR1916 0 mg/kg); every week (weeks 1 through 5; subcutaneous L-dopa methyl ester plus MR1916 0.015 mg/kg); and 1 week after discontinuation of daily MR1916 as washout for a test of baseline recovery (day 42: subcutaneous L-dopa methyl ester plus MR1916 0 mg/kg; see also Supplemental Fig. 1 ). Responses to the treatment combination, MR1916 plus oral L-dopa, were also scored once-weekly during the trial. All assessments were done in the morning and after overnight fast.
Behavioral Assessment
Motor evaluations were performed using a standardized primate motor scale (PMS) for MPTP-treated monkeys (see the scale in Supplementary Information). [30] [31] [32] The PMS has two parts: motor disability is rated in Part I (which is similar to Part III of the UPDRS used for PD patients), and LIDs are rated in Part II. 28 In addition, animals were assessed with the Drug Effects on the Nervous System (DENS) scale 33 to evaluate other potential neurological side effects of MR1916 or amantadine. This scale rates rapid changes in cortical (attentiveness and reactivity), motor (eye movement and involuntary movements), and autonomic functions (salivation, upper and lower gastrointestinal functions, and urinary function) after acute drug administration. The Kl€ uver board test (KBT) was also used to assess hand movement speed and fine motor skills. 34 In all trials, motor behavior in the off state (parkinsonian motor disability) was scored just before administration of MR1916 (or amantadine) followed by administration of L-dopa (subcutaneous or oral). After L-dopa administration, scores were taken starting at 30 minutes postinjection, and continuing every 20-minute interval during the duration of the motor response induced by L-dopa (on state). Animals were assessed directly by a blinded examiner and videotaped for deferred assessment by other blinded investigators.
Pharmacokinetics
The pharmacokinetics profile of MR1916 was examined in 3 M. fascicularis (all males, aged 3-5 years, weight 2-6 kg) under alert conditions (no sedative drugs were used). MR1916 was administered at doses of 0.005, 0.015, 0.05, and 0.15 mg/kg, subcutaneous alone or at 0.15 mg/kg, subcutaneous in combination with L-dopa methyl ester plus benserazide (25/6.25 mg/ kg, subcutaneous). Blood samples were collected at 15, 30, 60, 120, 180, 240, and 480 minutes after drug administration and were processed in duplicates. Using aliquots of plasma samples, MR1916 and L-dopa with internal standards were extracted with a protein precipitation method and analyzed by liquid chromatography with tandem mass spectrometry. Pharmacokinetics parameters were analyzed using Phoenix WinNonlin (version 6.1; Pharsight Corp, Palo Alto, CA). Detection limit of quantification was defined as 0.1 ng/mL for MR1916 and 10 ng/mL for L-dopa.
Statistical Analysis
Measurements of behavioral effects composed parametric data that were analyzed using one-or two-way analysis of variance for repeated measures followed by Fisher's least significant difference test when the F indicated significance. 30 Nonprocessed and normalized data (to control values) were used for analysis. In both acute and chronic coadministration tests, time course of LID, peak-dose LID (at 50 minutes postinjection), total LID (sum of LID scores obtained at all postinjection time points), MDS (motor disability score), and its AUC (area under the curve), movement time in KBT (time to complete the task before [0 minutes] and 90 minutes after treatment, animals were given up to 60 seconds to perform the task), and DENS scores were analyzed. All data are presented as mean 6 SEM. Statistical significance was determined at P < 0.05.
RESULTS
MR1916 Has Antidyskinetic Effect
In combination with the optimal dose of L-dopa, MR1916 at all the doses tested (ranging between 0.0015 and 0.05 mg/kg) significantly reduced LID. The most profound effect was found with 0.015 mg/ kg (Fig. 1A,B) . However, there was no significant difference in the effect size among the tested doses of MR1916. Both peak and total LID scores were significantly reduced by 38% and 46%, respectively by the most effective dose of MR1916 (0.015 mg/kg; Fig.  1C,D) . MR1916 effects on the dyskinesia induced by L-dopa optimal dose were similar to those of
amantadine at either dose 5 or 10 mg/kg (Fig. 1A-D) . Effects of MR1916 on LID were consistent across these animals that exhibited moderate-to-severe dyskinesias with mean peak-dose LID scores between 9.5 and 12.5 following optimal doses of L-dopa (see Supplementary Table 1 reduced LID (Fig. 1E,F) . At 0.015 mg/kg, MR1916 reduced peak and total LID scores by 40% and 45%, respectively. The highest dose tested (0.05 mg/kg) reduced peak and total LID scores by 66% and 70%, respectively (Fig. 1G,H) , which was more prominent than the effect of amantadine at 10 mg/kg (Fig. 1E-H) . At lower doses (0.0015 and 0.005 mg/kg), MR1916 had nonsignificant effect on dyskinesia induced by L-dopa suboptimal dose likely attributed to more subtle effects of MR1916 low doses and more variability in responses to suboptimal doses of L-dopa (Fig. 1G,H) .
MR1916 Does Not Affect the Therapeutic Antiparkinsonian Action of L-dopa
In combination with L-dopa optimal dose, MR1916 coadministration at any of the doses tested did not change MDS in the on state ( Fig. 2A,B) . In contrast, amantadine (5 and 10 mg/kg) significantly increased MDS (Fig. 2B) . Similarly, movement speed in KBT in the on state was not affected by MR1916 at any of the doses tested, but it was increased by amantadine at 10 mg/kg (Fig. 2C) . In combination with L-dopa suboptimal doses, MR1916 coadministration up to 0.015 mg/kg did not change MDS in the on state, but the highest dose of MR1916 (0.05 mg/kg) slightly increased MDS (Fig. 2D,E) . In this trial, amantadine (5 and 10 mg/kg) also reduced the beneficial effect of L-dopa on MDS (Fig. 2E) . Movement speed in KBT was also increased by the highest doses of MR1916 and amantadine (Fig. 2F) . These results indicate that the antiparkinsonian action of L-dopa optimal dose is not attenuated by MR1916. However, at lower (suboptimal) L-dopa doses, its antiparkinsonian action could be affected by high doses of MR1916, but, comparatively, amantadine effects present at a range of doses are more pronounced.
Analysis of plasma levels showed that MR1916 was rapidly absorbed with T max of less than 1 hour and had a dose-dependent increase of plasma concentrations (C max ) at doses between 0.005 and 0.15 mg/kg. The half-life of MR1916 was between 1 and 2 hours at the tested dose range. The pharmacokinetics profile of MR1916 was not changed by the addition of Ldopa/benserazide ( Fig. 3A; Supplementary Table 2) . Critically, for interpretation of MR1916 effects on dyskinesias, plasma levels of L-dopa did not change by the coadministration of MR1916 ( Fig. 3B ; Supplementary Table 2 ).
Anti-LID Effect of MR1916 Is Stable During Chronic Administration
Chronic administration of MR1916 (0.015 mg/kg) significantly reduced dyskinesias from the first week of daily treatment, and the effect was sustained during the whole period of chronic treatment (Fig. 4A,B) .
FIG. 2. MR1916 cotherapy does not affect the antiparkinson action of L-dopa. (A) Time course and (B) AUC of MDS with different doses of MR1916 or amantadine injected along with L-dopa optimal dose (subcutaneous). (C) Movement time (sec) in the KBT at 0 min (baseline) and 90 min following MR1916 or amantadine in combination with L-dopa optimal dose (subcutaneous). None of MR1916 doses affected MDS or the time in KBT. (D-F) MDS and time in KBT with different doses of MR1916 or amantadine injected along with L-dopa suboptimal dose (subcutaneous). Same graph details as in (A-C).
Only 0.05 mg/kg of MR1916 had a significant effect on MDS. Data are mean 6 SEM. *P < 0.05; **P < 0.01 versus control (MR1916 0 mg/kg). A refers to amantadine.
A P D E 1 0 A I N H I B I T O R R E D U C E S L I D
Peak and total LID scores induced by the suboptimal dose of L-dopa (subcutaneous) were significantly reduced across the weekly assessments of daily MR1916 treatment (Fig. 4C,D) . Furthermore, the effect of MR1916 on LID had a tendency to augment with prolonged exposure toward the end of this chronic trial. As expected, after 1 week of MR1916 washout, LID scores returned to baseline levels ( Fig.  4A-D) . Although responses to oral L-dopa are more variable in severely parkinsonian animals, the effect of daily MR1916 treatment on LID was also significant in the weekly comparisons of dyskinesias induced by the regular oral dose of L-dopa (Sinemet 25/100; Fig.  4E-H) . Chronic administration of MR1916 (0.015 mg/kg) that reduced LID had no significant effect on MDS across the weekly assessments with subcutaneous suboptimal dose or regular oral dose of L-dopa (Fig. 5A-D) . In addition, the improvement of movement speed (KBT) induced by L-dopa (subcutaneous) was unchanged across the weekly assessments of chronic MR1916 treatment (data not shown). Therefore, results show that anti-LID effects of MR1916 at 0.015 mg/kg subcutaneous are sustained following chronic treatment without interfering with the antiparkinsonian action of L-dopa.
MR1916 Is Well Tolerated
MR1916 did not induce overt adverse effects at any of the doses tested following acute or chronic administration to parkinsonian monkeys. To quantitate potential side effects, we used the DENS scale that evaluates functions of the nervous system commonly affected by psychoneurotropic agents (cognitive, sensorimotor, and autonomic functions). In acute treatment trials, items of the scale associated with cortical and autonomic function were unaffected (score 0) by MR1916 at any of the doses tested. There were no sedative effects as indicated by score 0 in the items of cortical function (attentiveness and reactivity). Only involuntary movements were scored in the DENS scale reflecting LID, which were reduced by MR1916 or amantadine. Thus, DENS scores were consistent with the PMS, Part II scores for LID. In chronic trials, again the only scores in the DENS scale were associated with involuntary movements and showed also the sustained LID reduction with daily MR1916 treatment (0.015 mg/kg). Furthermore, prolonged observation of the animals on daily bases in the chronic coadministration trial confirmed the absence of other abnormalities in the animal's behavior (such as increased aggressiveness or somnolence during daytime) or clinical conditions (the animal's parkinsonism and general health remained the same), indicating that chronic MR1916 treatment was well tolerated in parkinsonian monkeys.
DISCUSSION
A novel PDE10A inhibitor, MR1916, significantly reduced LID in the advanced primate model of PD, and the effect was maintained over chronic treatment for 5 weeks. The anti-LID effect of this drug was larger than that induced by amantadine at a dose range. This anti-LID effect is present without compromising the antiparkinsonian action of L-dopa or reducing its plasma levels. MR1916 was well tolerated by all animals, even after prolonged exposure during more than 1 month of daily administration. No adverse reaction was observed, and the use of specific measurements (DENS scale) showed absence of sedation or other common side effects of psychoneurotropic agents.
Further analysis of results in the acute tests indicates that all MR1916 doses could effectively reduce LID leaving MDS unchanged when the inhibitor was combined with optimal doses of L-dopa, which induce strong on responses and LID of consistent intensity. However, the therapeutic window of MR1916 changed with the suboptimal dose of L-dopa in this group of severely parkinsonian primates. These observations suggest that D2R antagonistic effects might predominate over the D1R-facilitating effects of PDE10A inhibition increasing cAMP/cGMP. The effects of MR1916 are consistent with those of other PDE10A inhibitors (TP-10 and papaverine), 35, 36 including antidyskinetic effects as shown in preliminary tests of TP-10 in rodents. 37 It is important to consider the changes that occur as parkinsonism progresses and motor responses to L-dopa evolve, particularly differential changes in sensitivity between D1R and D2R. 1, 6, 38 The effect of MR1916 high dose on . MR1916 significantly reduced LID in all analyses. Data are mean 6 SEM. *P < 0.05; **P < 0.01 versus control (baseline, L-dopa plus MR1916 0 mg/kg).
MDS was not observed with higher L-dopa doses in this group of primates with similarly advanced parkinsonism, indicating that the anti-LID efficacy of PDE10A inhibition without impacting MDS is likely dependent on the relation between D1R and D2R stimulation by L-dopa. Clearly, tests in models of milder parkinsonism as well as treatment combination with selective D1 or D2 agonists are necessary to fully address these points. Of critical importance are the results of the chronic MR1916 tests in primates. The pronounced anti-LID effect of the PDE10A inhibitor was sustained during daily treatment. Indeed, repeated exposure to MR1916 at the most effective dose did not induce tolerance; on the contrary, the reduction of LID deepened toward the end of the chronic trial. Tests of responses to oral L-dopa during the chronic coadministration also showed the MR1916 effect, even though in severely parkinsonian animals there is more variability in responses to oral L-dopa attributed to typical motor fluctuations. 39 Altogether, data indicate that PDE10A inhibition can have efficacy against LID even in severely parkinsonian and dyskinetic stages.
PDE10A is restricted to the striatum and highly expressed in SPNs, [15] [16] [17] where its catabolic action leads to reduction of cAMP and cGMP levels. This regulation is present in both SPN subtypes-direct and indirect pathway SPNs that express dopamine D1R and D2R, respectively. Because DA activation of D1R or D2R has opposite effects on cAMP/cGMP signaling pathways, PDE10A and DA interact differently in the direct and indirect pathways. It thus follows that the increased cAMP/cGMP levels resulting from PDE10A inhibition are synergistic with D1R signaling and antagonistic with D2R signaling. However, PDE10A metabolic action may be up-or downregulated depending on the levels of cyclic nucleotides, which likely change in SPNs of each pathway in conditions of chronic DA loss in PD. Studies in rodent models of PD have shown changes in cAMP/cGMP levels associated with the development of LID. 25, 26 Sancesario and colleagues showed that the anti-LID effect of amantadine in rodents is also related to changes in striatal levels of cAMP/cGMP. 25 Nevertheless, the available data regarding the regulation of cyclic nucleotides in SPNs of each pathway are not clear. [25] [26] [27] On the other hand, the roles of cAMP and cGMP for LID mechanisms may not be the same. Inhibitor of PDEs 5, 6 and 9 (zaprinast or UK343664), which increases cGMP, but not cAMP, improves abnormal involuntary movements in rodents. 26, 27 In the same line, upregulation of cGMP levels can rescue long-term depression at corticostriatal synapses, a form of synaptic plasticity that is lost in LID models. 27 Of note, PDE10A levels were found to be lower in patients with PD in a recent PET study. 40 However, these imaging data show enzyme reductions in striatum and globus pallidus, but PDE10A is not expressed in the latter. Also important, the interpretation of PET scans obtained after L-dopa treatment in relation to disease stage and motor states is unclear. PDE10A acts on both cGMP and cAMP; however, substrate affinity and other enzyme properties in the parkinsonian-dyskinetic setting are not known and may shed light on the mechanisms for its anti-LID effect. The critical point of PDE10A inhibition having synergism with D1R, but antagonism with D2R, activation cannot be construed as a global, net effect in each pathway resulting in the inhibitor anti-LID effect. Stimulation of D1R, which increases cAMP through the olfactory type G-protein a subunit, 14 is associated with multiple molecular markers of LID (dopamine-and cAMP-regulated phosphoprotein 32 kDa, protein phosphatase 1, mitogen-activated protein kinase, extracellular signal-related kinases 1 and 2, and the transcription factor, DFosB). [41] [42] [43] [44] [45] In addition, a member of the D2-like subfamily, the D3R, that also inhibits adenylyl cyclase and suppresses cAMP, may participate in the mechanisms of LID. Interestingly, the D3R contribution has been associated with a D1R-mediated mechanism according to a recent study in transgenic mice. 46 But activation of D2R also has an important role in the development of LID. For example, the interactions between D2R and Ca 21 /calmodulin-dependent protein kinase II or RGS9-2 (the regulators of G-protein signaling) have been linked to LID. [47] [48] [49] Important in relation to the present data, primate studies have shown both induction and control of LID by selective manipulation of either D1R or D2R mechanisms. [50] [51] [52] [53] It is thus likely that both striatal output pathways participate in the mechanisms of LID, which may result from multiple imbalances between individual SPN outputs between and within each pathway causing involuntary movements. 12, 24 It is thus likely that the dual action of PDE10A inhibition may blunt some of the signaling imbalances in either direction across single SPNs and thereby reduce LID.
The present tests of MR1916 in primates have clinical significance because results consistently showed anti-LID effects with a better pharmacological profile than the alternative treatment with amantadine. This study thus supports further development of the PDE10A inhibitor for the treatment of LID. A rapid path to advance MR1916 to clinical trials for PD is repurposing its clinically available form. Also important, this study provides key dose-response and pharmacokinetics data from primates to guide the experimental design of studies to assess efficacy in patients with PD.
